Cargando…
Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives
BACKGROUND: Financial toxicity (FT) is a notable concern for patients with breast cancer worldwide. The situation regarding FT in Japan, however, has not been well explored. This study examined FT in patients with breast cancer in Japan and presented an overview of the group study’s overall findings...
Autores principales: | Saeki, Sumito, Iwatani, Tsuguo, Kitano, Atsuko, Sakurai, Naomi, Tanabe, Yuko, Yamauchi, Chikako, Igarashi, Ataru, Kajimoto, Yusuke, Kuba, Sayaka, Hara, Fumikata, Sagara, Yasuaki, Ohno, Shinji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404186/ https://www.ncbi.nlm.nih.gov/pubmed/37310584 http://dx.doi.org/10.1007/s12282-023-01476-z |
Ejemplares similares
-
Correction: Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives
por: Saeki, Sumito, et al.
Publicado: (2023) -
Prospective observational study estimating willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A)
por: Iwatani, Tsuguo, et al.
Publicado: (2021) -
First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis
por: Shimoi, Tatsunori, et al.
Publicado: (2020) -
Surgical site infections in thyroid and parathyroid surgery in Japan: An analysis of the Japan Nosocomial Infections Surveillance database from 2013 to 2020
por: Iwatani, Tsuguo, et al.
Publicado: (2022) -
Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
por: Yamashita, Toshinari, et al.
Publicado: (2020)